Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Merck & Co., Inc.    MRK

MERCK & CO., INC.

(MRK)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
05/27/2020 05/28/2020 05/29/2020 06/01/2020 06/02/2020 Date
77.55(c) 79.04(c) 80.72(c) 79.56(c) 80.84(c) Last
12 241 380 12 585 990 12 900 691 5 991 955 10 832 972 Volume
+0.38% +1.92% +2.13% -1.44% +1.61% Change
More quotes
Financials (USD)
Sales 2020 47 328 M - -
Net income 2020 11 135 M - -
Net Debt 2020 13 943 M - -
P/E ratio 2020 18,5x
Yield 2020 2,96%
Sales 2021 50 938 M - -
Net income 2021 13 893 M - -
Net Debt 2021 10 977 M - -
P/E ratio 2021 15,1x
Yield 2021 3,17%
Capitalization 204 B 204 B -
EV / Sales 2020 4,61x
EV / Sales 2021 4,22x
Nbr of Employees 71 000
Free-Float 70,5%
More Financials
Company
Merck & Co., Inc. specializes in the development, production, and marketing of therapeutic products and vaccines sold under prescription. Net sales break down by activity as follows: - sale of pharmaceutical products (72.1%): for treating hypertension, osteoporosis, atherosclerosis, respiratory, bacterial and fungal, ophthalmologic, and urological diseases, acute migraine, hair loss in men, etc.; - sale of... 
Sector
Pharmaceuticals
Calendar
06/02 | 02:00pmPresentation
More about the company
Surperformance© ratings of Merck & Co., Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on MERCK & CO., INC.
02:48aCorporate Leaders Speak Out on Racism -- WSJ
DJ
06/02CEOs and Big Businesses Speak out on Racism, Police Violence
DJ
06/02MERCK : AstraZeneca and Merck - LYNPARZA Receives Positive Opinion from EU CHMP ..
AQ
06/02DAIICHI SANKYO : Announces Clinical Research Collaboration to Evaluate DS-1062 i..
AQ
06/01CEOs and Big Businesses Speak out on Racism, Police Violence
DJ
06/01AstraZeneca, Merck Get CHMP Positive Opinion for Lynparza in Pancreatic Cance..
DJ
06/01MERCK : Lynparza recommended for approval in EU by CHMP for BRCA-mutated metasta..
AQ
06/01MERCK : LYNPARZA® (olaparib) Receives Positive Opinion from EU CHMP for First-Li..
BU
05/29MERCK & CO., INC. : Submission of Matters to a Vote of Security Holders (form 8-..
AQ
05/28MERCK : KEYTRUDA® (pembrolizumab) plus LENVIMA® (lenvatinib) Combination Demonst..
BU
05/28MERCK : KEYTRUDA® (pembrolizumab) Superior to Standard of Care Chemotherapy in P..
BU
05/27BlackRock votes to split CEO, chairman roles at Exxon Mobil
RE
05/27Moderna rally loses steam over COVID-19 vaccine worries
RE
05/27Geopolitical Power Play Over Coronavirus Vaccine Leaves Drugmakers in the Mid..
DJ
05/27Merck Does Deals To Develop Vaccines -- WSJ
DJ
More news
News in other languages on MERCK & CO., INC.
02:48aCorporate Leaders Speak Out on Racism -- WSJ
06/02CEOs and Big Businesses Speak out on Racism, Police Violence
06/02MERCK : AstraZeneca and Merck - LYNPARZA Receives Positive Opinion from EU CHMP ..
06/02DAIICHI SANKYO : Announces Clinical Research Collaboration to Evaluate DS-1062 i..
06/01CEOs and Big Businesses Speak out on Racism, Police Violence
More news
Analyst Recommendations on MERCK & CO., INC.
More recommendations
Stock Trading Strategies
MERCK & CO., INC. - 05/26
The trend should regain control
BUY
More Stock Trading Analysis
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 20
Average target price 93,42 $
Last Close Price 80,84 $
Spread / Highest target 32,4%
Spread / Average Target 15,6%
Spread / Lowest Target 1,43%
EPS Revisions
Managers
NameTitle
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis CFO & Executive Vice President-Global Services
Sandy Tremps Vice President-R&D IT CIO
Thomas Henry Glocer Independent Director
Rochelle B. Lazarus Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
MERCK & CO., INC.-11.12%204 048
JOHNSON & JOHNSON1.63%390 579
ROCHE HOLDING AG6.64%296 977
PFIZER, INC.-7.71%200 863
NOVARTIS AG-10.13%189 331
ABBVIE INC.2.82%160 444